English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/99510
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH/CFHR1 hybrid gene

AuthorsRomán-Ortiz, E.; Mendizabal Oteiza, S.; Pinto, Sheila ; López Trascasa, Margarita; Sánchez-Corral, Pilar ; Rodríguez de Córdoba, Santiago
KeywordsCFH/CFHR1 hybrid gene
Eculizumab
Renal transplant recipient
Atypical hemolytic uremic syndrome
Issue DateJan-2014
PublisherSpringer
CitationPediatric Nephrology 29: 149- 153 (2014)
AbstractBackground: Atypical hemolytic uremic syndrome (aHUS) is a form of thrombotic microangiopathy (TMA) caused by dysregulation of the complement system. Outcomes of kidney transplantation are poor owing to aHUS recurrence and loss of graft. Patients carrying CFH mutations or CFH/CFHR1 hybrid genes present a very high risk of recurrence despite preventive plasmapheresis. Evaluation of recent data suggests that prophylactic eculizumab pretransplant might be the preferred therapy if available. Case-diagnosis/treatment: We report 3-year follow-up data in a 9-year-old boy with aHUS and successful renal transplant treated with prophylactic eculizumab without recurrence. He presented with aHUS at age 3, irreversible renal failure and uncontrolled severe hypertension with concentric left ventricular hypertrophy, recurrent acute pulmonary edema, and congestive heart failure despite five hypotensive agents and bilateral nephrectomy. Complement analysis demonstrated the presence of a CFH/CFHR1 hybrid gene inherited from his mother and a SNP risk CFH haplotype inherited from his father. Kidney transplant was performed with prophylactic eculizumab and subsequent fortnightly administration. Three years post-transplant, graft function remains stable (serum creatinine 0.9 mg/dl), hypertension is controlled, no left ventricular hypertrophy, no opportunistic infections, and negative clinical chemistry parameters for hemolysis. Conclusion: Eculizumab is a safe and effective therapy for preventing TMA recurrence and provides long-term graft function in aHUS with the CFH/CFHR1 hybrid gene. © 2013 IPNA.
Description16 p.-1 tab.-1 fig.
Publisher version (URL)http://dx.doi.org/10.1007/s00467-013-2591-8
URIhttp://hdl.handle.net/10261/99510
DOI10.1007/s00467-013-2591-8
ISSN0931-041X
E-ISSN1432-198X
Appears in Collections:(CIB) Artículos
Files in This Item:
File Description SizeFormat 
Roman-Ortiz et al_2014_Pediatric Nephrology.pdf190,29 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.